Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 12, 2025, titled "Zydus and Synthon sign an exclusive development, licensing, supply and commercialization agreement for a novel 505(B)(2) oncology product for the US market".
Press Release Feb 12 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a partnership with Synthon for the development and commercialization of a novel oncology product in the US market. Under this agreement, Synthon will handle the product's development and manufacturing, while Zydus will manage the NDA submission and commercialization. The product aims to reduce pill burden and enhance patient compliance, with a filing expected in the future.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 05 2025
- Press Release Jan 30 2025
- Press Release Jan 26 2025
- Press Release Jan 22 2025
- Press Release Jan 18 2025
Later from Zydus Lifesciences
- Press Release Feb 14 2025
- Press Release Feb 22 2025
- Press Release Feb 26 2025
- Press Release Mar 04 2025
- Press Release Mar 05 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences